Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYOS MYOS RENS Technology		$3.35	$0.74 ▼ $3.85	$16.70M	1.08	1.68 million shs	N/A
PHIO Phio Pharmaceuticals	$0.64 -1.6%	$0.79	$0.50 ▼ $6.85	$2.98M	1.44	131,301 shs	61,688 shs
XTLB XTL Biopharmaceuticals	$2.44 -1.2%	$3.99	$1.73 ▼ $6.69	$13.46M	1.21	1.58 million shs	11,935 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYOS MYOS RENS Technology	0.00%	0.00%	-2.14%	-55.37%	+358.19%
PHIO Phio Pharmaceuticals	-1.01%	-9.22%	-35.40%	-5.93%	-84.44%
XTLB XTL Biopharmaceuticals	-1.21%	-11.59%	+134.62%	+190.48%	+78.32%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	2.4064 of 5 stars	3.5	5.0	0.0	0.0	0.0	2.5	0.6
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	3.00	Buy	$4.00	529.92% Upside
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest PHIO, XTLB, and MYOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/6/2024	PHIO Phio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYOS MYOS RENS Technology	$1.03M	0.00	N/A	N/A	$0.13 per share	0.00
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$2.06 per share	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	$0.73 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYOS MYOS RENS Technology	-$4.26M	N/A	N/A	N/A	N/A	-277.82%	-166.68%	-104.95%	N/A
PHIO Phio Pharmaceuticals	-$10.83M	-$5.93	N/A	∞	N/A	N/A	-134.66%	-105.86%	5/9/2024 (Estimated)
XTLB XTL Biopharmaceuticals	-$1.35M	-$0.42	N/A	∞	N/A	N/A	-73.05%	-68.83%	5/21/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYOS MYOS RENS Technology	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYOS MYOS RENS Technology	0.11	3.78	1.94
PHIO Phio Pharmaceuticals	N/A	5.70	5.71
XTLB XTL Biopharmaceuticals	N/A	14.09	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
MYOS MYOS RENS Technology	4.97%
PHIO Phio Pharmaceuticals	57.31%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
MYOS MYOS RENS Technology	45.30%
PHIO Phio Pharmaceuticals	0.77%
XTLB XTL Biopharmaceuticals	29.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
MYOS MYOS RENS Technology	15	12.19 million	N/A	Not Optionable
PHIO Phio Pharmaceuticals	9	4.59 million	4.56 million	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

PHIO, XTLB, and MYOS Headlines

Source	Headline
	U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% msn.com - March 20 at 8:50 PM
	US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views msn.com - March 20 at 3:48 PM
	Dow Surges 350 Points; Fed Holds Rates Steady markets.businessinsider.com - March 20 at 3:48 PM
	Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher markets.businessinsider.com - March 20 at 3:48 PM
	XTL To Aquire The Social Proxy globenewswire.com - March 20 at 10:15 AM
	XTL Biopharmaceuticals Ltd ADR (XTLB) investing.com - February 17 at 10:28 AM
	Call for Proposals raps.org - February 11 at 2:00 PM
	XTL Biopharmaceuticals Ltd (H2K2.MU) finance.yahoo.com - October 23 at 11:13 PM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finanznachrichten.de - October 23 at 12:16 AM
	XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finanznachrichten.de - October 21 at 8:22 AM
	XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel finance.yahoo.com - October 20 at 7:35 PM
	XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency finance.yahoo.com - October 20 at 7:35 PM
	Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment? aaii.com - March 30 at 3:19 PM
	XTLB XTL Biopharmaceuticals Ltd. seekingalpha.com - October 1 at 8:47 PM
	X T L Biopharmaceuticals Ltd reuters.com - August 8 at 10:32 PM
	LIFE, TBLT and XTLB among pre market gainers seekingalpha.com - July 23 at 7:53 AM
	XTL Biopharmaceuticals Year to Date Total Returns (Daily) ycharts.com - December 18 at 11:24 PM
	XTL Biopharmaceuticals Dividend Per Share (TTM) ycharts.com - December 18 at 1:03 AM
	XTL Biopharmaceuticals Ltd. (XTLB) uk.finance.yahoo.com - December 15 at 10:18 AM
	X.T.L. Biopharmaceuticals Ltd. - ADR money.usnews.com - September 26 at 12:03 AM
	XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Up 1.8% This Year: What Should You Expect Next? stocksregister.com - August 23 at 4:44 PM
	Is XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Expensive At $4.67? Here’s How To Know. marketingsentinel.com - August 20 at 5:09 PM
	How Is XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) Expected To Fare In The Coming Months? marketingsentinel.com - July 26 at 9:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MYOS RENS Technology

NASDAQ:MYOS

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

Phio Pharmaceuticals

NASDAQ:PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

XTL Biopharmaceuticals

NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial